It's been two years since bedinvetmab was launched as a treatment for the pain associated with osteoarthritis - quickly followed by frunevetmab. During that time Matt has lectured around the world on the topic. This podcast brings together a number of questions that have been raised as part of those lectures - and we always say that if someone has a question, then 10 are people are thinking the same thing!
After this podcast you will have a better understanding of the anti nerve growth factor agents. If you have questions, we would love to help. Please use the contact box to send us a message.
Don't forget that we offer a telemedicine service - so for case advice, please ask for our help!
Reflective learning
What further questions does this podcast content raise for you?
How will this understanding impact the management of your current and future patients?
Learning actions
Revise the mechanism of action of anti nerve growth factor agents (both references below)
Review the data sheet (summary of product characteristics) for bedinvetmab (Librela/Beransa) and frunevetmab (Solensia).
Practice discussion
As a practice team do we feel that anti-NGF agents are a first line treatment for OA in dogs and cats?
References
Enomoto M, Mantyh PW, Murrell J, Innes JF, Lascelles BDX. Anti-nerve growth factor monoclonal antibodies for the control of pain in dogs and cats. Vet Rec. 2019 Jan 5;184(1):23. doi: 10.1136/vr.104590. Epub 2018 Oct 27. PMID: 30368458; PMCID: PMC6326241.
Schmelz M, Mantyh P, Malfait AM, Farrar J, Yaksh T, Tive L, Viktrup L. Nerve growth factor antibody for the treatment of osteoarthritis pain and chronic low-back pain: mechanism of action in the context of efficacy and safety. Pain. 2019 Oct;160(10):2210-2220. doi: 10.1097/j.pain.0000000000001625. PMID: 31145219; PMCID: PMC6756297.

Ver todos los episodios